Navigation Links
TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients

TAXUS Liberte has more CE Mark-approved indications than any other

drug-eluting stent

NATICK, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that its TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system has received European CE Mark approval for use in patients with diabetes.(1) Boston Scientific submitted data showing the TAXUS Liberte stent has benefited diabetic patients with coronary artery disease, both in clinical trials and real-world registries. This approval means the TAXUS Liberte stent system now has more CE Mark- approved indications than any other drug-eluting stent, allowing treatment of a wide range of patients including many of those at high risk. The TAXUS Liberte stent system is the most frequently used drug-eluting stent system in Europe.

"Achieving CE Mark approval for TAXUS Liberte in patients with diabetes is an important milestone," said David McFaul, Boston Scientific Senior Vice President, International. "As a leader in devices for the treatment of cardiovascular disease, Boston Scientific's goal is to provide patients with the most advanced treatment options available. In this case, we are offering another specific solution for diabetic patients outside the United States, who are typically at higher risk for adverse events compared to non-diabetic patients."

Combined data from four TAXUS ATLAS trials supported the efficacy and safety of the TAXUS Liberte stent system in diabetic patients.(2) The trials examined 1,529 patients treated with the TAXUS Liberte stent system, 413 of whom had diabetes, and reported similar rates of target lesion revascularization (TLR, or retreatment), cardiac death, myocardial infarction (MI, or heart attack) and stent thrombosis (clotting) between diabetic and non-diabetic stent recipients after adjustment for differences in risk at baseline.

Diabetes affects more than 200 million people worldwide and is expected to affect 360 million people by 2030.(3) Approximately half of all patients presenting with coronary artery disease (CAD) in Europe have diabetes.(4) Diabetic patients with CAD often have poorer outcomes after revascularization procedures because their blood vessels tend to build up more plaque than the vessels of non-diabetic patients, and their CAD advances more quickly. CAD is the most common cause of death among European adults with diabetes.(5)

As a result of the expanded CE Mark, the TAXUS Liberte stent system in the European Union is indicated for treatment of de novo and restenotic lesions or total occlusions in patients with coronary artery disease -- angina; silent ischemia; acute myocardial infarction -- to improve luminal diameter and reduce restenosis within the stent and at the stent edges in native coronary arteries. The TAXUS Liberte stent system is also indicated for patients with concomitant diabetes mellitus as well as treatment of abrupt or threatened closure in patients with failed interventional therapy.

The TAXUS Liberte stent is available outside the United States in a wide range of sizes to treat a diversity of vessel sizes and lesion lengths seen in patients with coronary artery disease.

The TAXUS Liberte stent system is pending approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

617-459-2703 (mobile)

Investor Relations

Boston Scientific Corporation


(1) For patients with concomitant diabetes mellitus.

(2) Ormiston J, Mahmud E, Mandinov L, et al. TAXUS Liberte attenuates the

risk of restenosis in diabetics: results from the TAXUS ATLAS Program.

Presented at the annual Transcatheter Cardiovascular Therapeutics

symposium, Washington, D.C., 20-25 October 2007.

(3) Wild S, Roglic G, Green A, et al. Global prevalence of diabetes:

estimates for the year 2000 and projections for 2030. Diabetes Care


(4) Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal

glucose regulation in patients with coronary artery disease across

Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J


(5) Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-

diabetes, and cardiovascular diseases: executive summary. The Task

Force on Diabetes and Cardiovascular Diseases of the European Society

of Cardiology (ESC) and of the European Association for the Study of

Diabetes (EASD). Eur Heart J 2007;28(1):88-136.

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Diabetes appears to increase risk of death for patients with acute coronary syndromes
3. Treating depression may improve recovery of heart rate variability following coronary syndromes
4. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
5. Study Links Coronary Disease, Colon Cancer
6. Coronary Disease Might Toughen Up Heart
7. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
8. Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
9. Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
10. Coronary Artery Calcium May Raise Womens Heart Risk
11. Abdominal Fat Tied to High Risk for Coronary Trouble
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... $3,296 in property taxes a year. In some states—like New York, New Jersey, ... By contrast, many overseas retirement havens have extremely low property-tax rates, which contributes ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
Breaking Medicine Technology: